- Home
- BAK vs ETNB Comparison
BAK vs ETNB Comparison
Compare BAK & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BAK
- ETNB
- Stock Information
- Founded
- BAK 1972
- ETNB 2018
- Country
- BAK Brazil
- ETNB United States
- Employees
- BAK N/A
- ETNB N/A
- Industry
- BAK Major Chemicals
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- BAK Industrials
- ETNB Health Care
- Exchange
- BAK Nasdaq
- ETNB Nasdaq
- Market Cap
- BAK 1.3B
- ETNB 1.5B
- IPO Year
- BAK N/A
- ETNB 2019
- Fundamental
- Price
- BAK $3.53
- ETNB $8.87
- Analyst Decision
- BAK Buy
- ETNB Strong Buy
- Analyst Count
- BAK 2
- ETNB 10
- Target Price
- BAK $7.50
- ETNB $27.22
- AVG Volume (30 Days)
- BAK 935.3K
- ETNB 1.4M
- Earning Date
- BAK 08-07-2025
- ETNB 08-07-2025
- Dividend Yield
- BAK N/A
- ETNB N/A
- EPS Growth
- BAK N/A
- ETNB N/A
- EPS
- BAK N/A
- ETNB N/A
- Revenue
- BAK $14,266,076,929.00
- ETNB N/A
- Revenue This Year
- BAK $4.10
- ETNB N/A
- Revenue Next Year
- BAK $11.25
- ETNB N/A
- P/E Ratio
- BAK N/A
- ETNB N/A
- Revenue Growth
- BAK 10.48
- ETNB N/A
- 52 Week Low
- BAK $2.80
- ETNB $4.16
- 52 Week High
- BAK $7.71
- ETNB $11.84
- Technical
- Relative Strength Index (RSI)
- BAK 62.43
- ETNB 43.45
- Support Level
- BAK $3.24
- ETNB $8.46
- Resistance Level
- BAK $3.63
- ETNB $9.47
- Average True Range (ATR)
- BAK 0.14
- ETNB 0.46
- MACD
- BAK 0.05
- ETNB -0.02
- Stochastic Oscillator
- BAK 87.35
- ETNB 33.33
About BAK Braskem SA ADR
Braskem SA manufactures and sells chemicals, petrochemicals, fuels, and utilities. The company's geographical segments include Brazil; the United States and Europe and Mexico. It derives a majority of its revenue from Brazil. It produces olefins, such as ethylene, polymer and chemical-grade propylene, butadiene, and butene-1; fuels, such as automotive gasoline, liquefied petroleum gas, or LPG, ethyl tertiary-butyl ether, or ETBE, and methyl tertiary-butyl ether, or MTBE; intermediates, such as cumene and others.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).